HIGHFDA DRUG
Exela Pharma Recalls Sodium Bicarbonate Injection Over Arsenic Risk
Exela Pharma Sciences recalled 4.2% Sodium Bicarbonate Injection on July 30, 2025, due to arsenic contamination. The recall affects single-dose vials distributed nationwide. Consumers and healthcare providers must stop using the product immediately.
SODIUM BICARBONATE
Failed Impurities/Degradation